Sagent Pharmaceuticals, a division of Nichi-Iko Pharmaceutical Co Ltd, announced earlier this month that it has purchased an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.
Sagent Pharmaceuticals, a division of Nichi-Iko Pharmaceutical Co Ltd, announced earlier this month that it has purchased an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.
The site is capable of approving both small-molecule drugs and biologics. While Sagent’s chief executive officer (CEO), Peter Kaemmerer, PhD, said in a statement that while it intends to continue to manufacture some products for Xellia, the acquisition of the Raleigh site “will enable production of lyophilized formulations of our future biosimilar product offerings.”
Yuichi Tamura, president and CEO of Nichi-Iko, said in a statement, “We applaud this acquisition as another big step forward for Nichi-Iko and Sagent, further strengthening our competitiveness and capabilities in the key US market. The acquisition of this manufacturing facility, our first in the [United States], will have an important role as we strive to fulfill our mission of providing value-added, high quality generic products which meet the needs of patients and their families in the global market.”
Nichi-Iko has already begun its foray into biosimilars; the company received approval for its biosimilar infliximab, NI-071, in Japan in 2017, and subsequently began a phase 3 clinical program in the United States with an eye toward eventual FDA approval. The company also disclosed that it has consulted with the FDA concerning a demonstration of interchangeability for the biosimilar with the reference infliximab, Remicade.
Furthermore, in June 2018, the company announced that it had forged a partnership with Lupin for the distribution, promotion, and sale of a proposed etanercept biosimilar, YLB113, in Japan. In the Republic of Korea, Nichi-Iko’s Aprogen affiliate last year completed construction of a biologics production facility to provide a stable supply of biosimilars for the US and Japanese markets.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.